Maralixibat is approved. The science chapter is closed for Alagille Syndrome and PFIC. Like Insmed's brensocatib, this audit reaches its boundary quickly: the load-bearing mechanism is validated by regulatory approval and long-term patient data. What remains is a commercial execution story and a pipeline expansion bet — biliary atresia and additional cholestatic diseases in the EXPAND Phase 3.
The forensic audit's contribution here is to confirm which risks are science risks (few, manageable) and which are commercial and pipeline risks (the actual active bets). The slight Q4 2025 trim suggests NicHealth is managing position size, not exiting conviction.
Maralixibat, by inhibiting the apical sodium-dependent bile acid transporter (ASBT/IBAT) in the ileum and reducing bile acid reabsorption, durably reduces cholestatic pruritus and liver disease progression in ALGS and PFIC — and will demonstrate equivalent benefit in biliary atresia and additional rare cholestatic diseases, expanding the addressable market beyond current approved indications.
| # | Source | What It Says | What Was Claimed | Gap | Conf. |
|---|---|---|---|---|---|
| 1 | Hofmann & Hagey, J Lipid Res, 2008; Dawson et al., J Lipid Res, 2009 (ASBT biology) | ASBT (SLC10A2) is the primary transporter for active bile acid reabsorption in the terminal ileum. Inhibiting ASBT reduces enterohepatic circulation of bile acids, lowering systemic and hepatic bile acid burden. In cholestatic diseases where bile acid accumulation is pathogenic, ASBT inhibition is mechanistically appropriate. | ASBT inhibition will reduce bile acid burden and thereby reduce cholestatic pruritus and liver injury. | None. ASBT biology is textbook hepatology. The role of bile acid accumulation in cholestatic pruritus and liver injury is independently established across decades. | HIGH |
| 2 | Shneider et al., Hepatology, 2022 (ICONIC trial, maralixibat in ALGS); Gonzales et al., Hepatology, 2021 (MARCH-PFIC Phase 3) | ICONIC (ALGS, n=31): maralixibat reduced serum bile acids and pruritus with clinically meaningful effect sizes sustained over 5 years. MARCH-PFIC: improved pruritus across PFIC subtypes including previously unstudied genetic types. Long-term data shows improvements maintained over time. Transplant-free survival data supportive. | Maralixibat produces durable, clinically meaningful benefit in ALGS and PFIC. | None. FDA approved both indications. The science is ratified by the regulatory record. Long-term extension data adds to the certainty — patients maintained benefit over multiple years without new safety signals. | HIGH |
| 3 | EXPAND Phase 3 design (biliary atresia + additional rare cholestatic diseases); enrollment completed March 2026 | EXPAND is a randomized, double-blind, placebo-controlled Phase 3 study in patients aged 6 months+ with rare cholestatic liver diseases including biliary atresia. Enrollment completed March 2026. Top-line data expected in 2027. | Maralixibat's ASBT mechanism will reduce cholestatic pruritus in biliary atresia and additional rare cholestatic diseases beyond ALGS and PFIC. | EXTRAPOLATION — BILIARY ATRESIA IS PATHOPHYSIOLOGICALLY DISTINCT. Biliary atresia involves obstruction of the bile ducts (structural/inflammatory), not a transporter or genetic deficiency. ASBT inhibition reduces bile acid reabsorption — but if the bile duct is obstructed, bile acids may accumulate through different pathways than in ALGS/PFIC. The mechanism is plausible but the translation is not guaranteed. Biliary atresia Phase 3 outcome is the key open question for pipeline expansion valuation. | MEDIUM |
The ALGS and PFIC science chains are closed — FDA-approved, long-term data positive, EU approved. The active bet in the Mirum position is pipeline expansion: biliary atresia and other rare cholestatic diseases in EXPAND. The mechanism extrapolation from ALGS/PFIC (genetic bile acid transporter deficiencies) to biliary atresia (obstructive bile duct disease) is plausible but carries meaningful uncertainty. EXPAND top-line data in 2027 is the next thesis-defining event.
ASBT inhibition mechanism: established. Maralixibat efficacy in ALGS and PFIC: FDA-approved, long-term data positive, EU approved. Commercial execution in existing indications: launched, patients on drug.
EXPAND pipeline expansion into biliary atresia. Mechanistically plausible but biliary atresia's obstructive pathophysiology differs from the genetic transporter deficiencies underlying ALGS/PFIC. EXPAND data in 2027 is the resolution. The position's current valuation should reflect this as an unconfirmed upside option, not a confirmed extension.
The slight Q4 2025 trim (–3,677 shares) is consistent with the audit's verdict: the science is de-risked, the commercial story is executing, but EXPAND's biliary atresia outcome is uncertain. Holding a moderately sized position ($16.9M) while awaiting EXPAND data is forensically correct. This is not a position to dramatically increase before EXPAND top-line data.
EXPAND enrollment completed March 2026. Science is de-risked on approved indications. Monitor: quarterly net revenue in ALGS/PFIC, EXPAND enrollment milestones, and odevixibat competitive activity. No catalyst until 2027 EXPAND data unless commercial results surprise significantly in either direction.
Forward kill condition: EXPAND fails in biliary atresia, and quarterly revenues plateau below consensus — signals the commercial ceiling is lower than modeled and pipeline expansion is not materializing.